Breaking News, Promotions & Moves

Astellas Restructures Management

Establishes new top management positions and makes personnel changes.

Astellas has changed its management structure, establishing new top management positions and making personnel changes. The goal of the change is to promote drug discovery activities swiftly and efficiently from the early stages of research through to commercialization with a patient-centric approach.


See the changes below.

Establishment and Appointment of Chief Research & Development Officer (CRDO)

As an innovation engine, Astellas is integrating its research and development teams with the Primary Focus Leads. Effective April 1, 2025, Astellas will establish the position of CRDO, overseeing these divisions, with Tadaaki Taniguchi, M.D., Ph.D., the current Chief Medical Officer (CMO), appointed to this role.

Establishment and Appointment of Chief Commercial & Medical Affairs Officer (CCMAO)

To build customer engagement that leads the pharmaceutical industry, Astellas will integrate the current Commercial and Medical Affairs functions while maintaining the independence of each function. Effective April 1, 2025, it will establish the position of CCMAO, overseeing these divisions, with Claus Zieler, the current Chief Commercial Officer (CCO), appointed to this role.

With this change in management structure, the roles of CMO, CCO, and Chief Scientific Officer (CScO) will be eliminated. Yoshitsugu Shitaka, Ph.D., the current CScO, will resign effective March 31, 2025.

Appointment of Chief Manufacturing Officer (CMfgO)

Rao V. Mantri, Ph.D. will be appointed to the new CMfgO, as of April 1, 2025. He joined Astellas on February 3, 2025, and has extensive experience in a global pharmaceutical company, focusing on innovation in product development, manufacturing, and supply, as well as being involved in management. Hideki Shima, the current CMfgO, will resign effective March 31, 2025.

Establishment and Appointment of General Counsel and Chief Ethics & Compliance Officer (GC & CECO)

Astellas will also consolidate legal, intellectual property, quality assurance, and ethics & compliance into a single top management position. Effective April 1, 2025, it will establish the position of GC & CECO, with Tatjana Dragovic appointed to this role. Since joining Astellas in 2007, she has held leadership roles in legal and ethics & compliance. Catherine Levitt, the current GC, will resign effective March 31, 2025.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics